RIVM Report 703719064Appendix H Provisional dr<strong>in</strong>k<strong>in</strong>g water limitsToxicological limits for party drugs <strong>in</strong> dr<strong>in</strong>k<strong>in</strong>gwater sourcesAdvice requested by: Drs. N.G.F.M. van der Aa (RIVM/IMG)Date requested: 17-03-2010Date advice: 19-07-2010Date <strong>of</strong> revision1: 16-11-2010Advice preparation: Dr B.M. van de Ven (RIVM/SIR)Advice review: Ing. P.J.C.M. Janssen (RIVM/SIR)Project no. RIVM: M/703719/10/BBPORS no.: 12658MethodIn the present document, provisional toxicological limits for party drugs <strong>in</strong>dr<strong>in</strong>k<strong>in</strong>g-water sources are determ<strong>in</strong>ed, to be used with<strong>in</strong> RIVM projectM/703719/10/BB: explor<strong>in</strong>g measurements <strong>in</strong> dr<strong>in</strong>k<strong>in</strong>g water (sources). Limitderivation is based on allocation <strong>of</strong> 10% <strong>of</strong> the ADI (acceptable daily <strong>in</strong>take) orthe MRL (maximum residue limit) for milk determ<strong>in</strong>ed for veter<strong>in</strong>ary medic<strong>in</strong>esto dr<strong>in</strong>k<strong>in</strong>g water. In the calculation, an average bodyweight <strong>of</strong> 60 kg <strong>and</strong> adr<strong>in</strong>k<strong>in</strong>g water <strong>in</strong>take <strong>of</strong> 2 litres/day are assumed. For drugs not used as aveter<strong>in</strong>ary medic<strong>in</strong>e, the SIR/SEC database was searched to determ<strong>in</strong>e if anexist<strong>in</strong>g ADI was available. When no ADI was available from this database, alimited literature search was performed <strong>in</strong> Toxnet (queries us<strong>in</strong>g the name <strong>of</strong> thedrug <strong>and</strong> the words ‘toxicity’ <strong>and</strong> ‘review’). Abstracts were screened for ADIs ortoxicologically relevant data. If no ADI or MRL was available, a provisionaldr<strong>in</strong>k<strong>in</strong>g-water limit was determ<strong>in</strong>ed from the lowest pharmacological effectivedose <strong>and</strong> a safety factor <strong>of</strong> 100, an average body weight <strong>of</strong> 60 kg <strong>and</strong> aconsumption <strong>of</strong> 2 litres <strong>of</strong> dr<strong>in</strong>k<strong>in</strong>g water per day.Although it is known that some drugs <strong>in</strong>teract at pharmacologically effectivedoses, no <strong>in</strong>formation was available on their possible <strong>in</strong>teraction at the level <strong>of</strong>the proposed dr<strong>in</strong>k<strong>in</strong>g-water limits. Therefore, no attempt was made todeterm<strong>in</strong>e dr<strong>in</strong>k<strong>in</strong>g-water limits for comb<strong>in</strong>ations <strong>of</strong> drugs. Only for drugsbelong<strong>in</strong>g to the same chemical group that are known to have the samemechanism <strong>of</strong> action a dr<strong>in</strong>k<strong>in</strong>g water limit was derived for the whole group.Benzoylecgon<strong>in</strong>eCASnr: 519-09-5Chemical name:(1R,2R,3S,5S)-3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acidBenzoylecgon<strong>in</strong>e is a (O-demethylated) metabolite <strong>of</strong> coca<strong>in</strong>e, not used as adrug itself but found <strong>in</strong> blood <strong>and</strong> ur<strong>in</strong>e after coca<strong>in</strong>e use. No evaluation <strong>of</strong>benzoylecgon<strong>in</strong>e is present <strong>in</strong> the SIR/RIVM database. No ADI or oraltoxicological <strong>in</strong>formation was found. Only some comparative toxicological studieshave been performed <strong>in</strong> order to assess whether coca<strong>in</strong>e metabolites are moreor less toxic then coca<strong>in</strong>e itself. In a study <strong>of</strong> Morishima et al., it was determ<strong>in</strong>edthat doses <strong>of</strong> benzoylecgon<strong>in</strong>e necessary to produce mild neurobehavioralPage 81 <strong>of</strong> 90
RIVM Report 703719064changes <strong>in</strong> rat after <strong>in</strong>travenous adm<strong>in</strong>istration, were 30-fold higher than thosefor coca<strong>in</strong>e <strong>and</strong> that benzoylecgon<strong>in</strong>e was not lethal, even at doses 100 timesgreater than those <strong>of</strong> coca<strong>in</strong>e (Morishima et al., 1999). Infusion withbenzoylecgon<strong>in</strong>e resulted <strong>in</strong> later onset <strong>of</strong> convulsions <strong>and</strong> respiratory <strong>and</strong>circulatory arrest <strong>in</strong> rats than after <strong>in</strong>fusion with coca<strong>in</strong>e (Metz <strong>and</strong> Virag, 1995).Furthermore, <strong>in</strong> vitro, benzoylecgon<strong>in</strong>e <strong>in</strong>hibited the development <strong>of</strong> embryos toblasocysts only at higher concentrations than did coca<strong>in</strong>e (Kaufmann <strong>and</strong>Armant, 1992). These results <strong>in</strong>dicate that benzoylecgon<strong>in</strong>e is less toxic thancoca<strong>in</strong>e. Based on this conclusion, the provisional dr<strong>in</strong>k<strong>in</strong>g-water limit forcoca<strong>in</strong>e <strong>of</strong> 0.02 mg/L (see below) will be safe for benzoylecgon<strong>in</strong>e as well.Therefore, a provisional dr<strong>in</strong>k<strong>in</strong>g-water limit for benzoylecgon<strong>in</strong>e is proposed <strong>of</strong>0.02 mg/L.Coca<strong>in</strong>eCASnr: 50-36-2Synonym: Benzoylmethylecgon<strong>in</strong>eChemical name:Methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acidCoca<strong>in</strong>e is a strong central nervous system stimulant that <strong>in</strong>duces euphoriceffects. No evaluation <strong>of</strong> coca<strong>in</strong>e is present <strong>in</strong> the SIR/RIVM database. Coca<strong>in</strong>e isnot used as a veter<strong>in</strong>ary drug. It is used <strong>in</strong> human medic<strong>in</strong>e but only as topicalanaesthetic for ophthalmological procedures <strong>and</strong> for membranes <strong>of</strong> the nose <strong>and</strong>throat (Baselt, 2004). Typical use levels for addicts to coca<strong>in</strong>e are not provided<strong>in</strong> literature. In the IPCS monograph on coca<strong>in</strong>e it is mentioned that “thetherapeutic use rate” is 1 to 3 mg/kg bw (IPCS), without specification <strong>of</strong> theroute <strong>of</strong> adm<strong>in</strong>istration. In a study which <strong>in</strong>vestigates “low doses <strong>of</strong> oralcoca<strong>in</strong>e”, levels <strong>of</strong> 50 mg/ person were used (0.8 mg/kg bw/d) (Epste<strong>in</strong> et al.,1999). The effects <strong>of</strong> coca<strong>in</strong>e have been exhaustively <strong>in</strong>vestigated but moststudies concentrate on <strong>abuse</strong>, overdose, addiction <strong>and</strong> treatment <strong>of</strong> addicts. Nosuitable toxicological data are available for the derivation <strong>of</strong> an ADI. Therefore, aprovisional ADI is derived from the lowest known oral pharmacological dose level<strong>of</strong> 0.8 mg/kg bw/day, us<strong>in</strong>g a safety factor <strong>of</strong> 100. This leads to a provisionalADI <strong>of</strong> 0.008 mg/kg bw. Allocat<strong>in</strong>g 10% <strong>of</strong> this ADI to dr<strong>in</strong>k<strong>in</strong>g-water, aprovisional dr<strong>in</strong>k<strong>in</strong>g-water limit is derived <strong>of</strong> 0.02 mg/L (0.008 mg/kg bw/d /10* 60 kg bw / 2 L).Norcoca<strong>in</strong>eCASnr: 18717-72-1Chemical name: Methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-azabicyclo[3.2.1]octane-2-carboxylic acidNorcoca<strong>in</strong>e is a (N-demethylated) metabolite <strong>of</strong> coca<strong>in</strong>e, not used as a drugitself but found <strong>in</strong> blood <strong>and</strong> ur<strong>in</strong>e after coca<strong>in</strong>e use. No evaluation <strong>of</strong> norcoca<strong>in</strong>eis present <strong>in</strong> the SIR/RIVM database. No ADI or oral toxicological <strong>in</strong>formationwas found. Only a few comparative toxicological studies have been performed <strong>in</strong>order to assess whether coca<strong>in</strong>e metabolites are more or less toxic than coca<strong>in</strong>eitself. In a study <strong>of</strong> Morishima et al., it was determ<strong>in</strong>ed that doses <strong>of</strong> norcoca<strong>in</strong>enecessary to produce toxic effects were smaller than those <strong>of</strong> coca<strong>in</strong>e whenadm<strong>in</strong>istered systemically to rats (Morishima et al., 1999). In another study,norcoca<strong>in</strong>e <strong>in</strong>fusion resulted <strong>in</strong> earlier onset <strong>of</strong> convulsions <strong>and</strong> respiratory arrest<strong>in</strong> conscious rats than with coca<strong>in</strong>e. Onset <strong>of</strong> circulatory arrest was also earlierwith norcoca<strong>in</strong>e (Metz <strong>and</strong> Virag, 1995). Coca<strong>in</strong>e was found to producePage 82 <strong>of</strong> 90